Image Source : Emergency Dentist London
India’s pain relief industry has doubled in size over five years, now valued at Rs 15,905 crore as of May 2025. This explosive 18% CAGR outpaces the broader OTC market, which grew at 6% CAGR to Rs 80,000 crore.
Key Highlights
- Analgesics dominate with 75% market share; paracetamol leads the pack
- Rubefacients (topical creams and gels) like Omnigel are gaining traction
- Over 2,700 brands now compete, up from 1,552 in 2020
- Popular drugs include Dolo, Zerodol SP, Ultracet, Calpol, Saridon, and Ibugesic Plus
Drivers of Growth
- Urban lifestyle shifts: gym injuries, chronic stress, and sedentary habits
- Post-Covid awareness: consumers now prioritize immediate pain relief
- Ease of access: prescription drugs increasingly available OTC
- Rising self-medication despite medical warnings
Emerging Concerns
- Experts warn of kidney damage and other risks from prolonged use
- Self-medication trend extends to derma products, now a Rs 14,854 crore market
- Gen Z is driving demand for skin creams and anti-inflammatory solutions
Industry Voices
- Cipla Health’s MD cites demand for fast, convenient formats
- Bayer’s South Asia head notes changing attitudes toward pain and productivity
- Physicians link rising demand to obesity, anxiety, and lack of sleep
Outlook
Pain relief is no longer just a symptom fix—it’s a lifestyle staple. But as convenience rises, so does the need for caution.
Source: The Economic Times, PharmaTrac, ET Pharma
Advertisement
Advertisement